Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 125,960

Document Document Title
WO/2017/126655A1
The present invention provides: a method for screening for a pain-preventing substance, characterized by comprising selecting a substance capable of inhibiting the expression of Robo4 or a substance capable of inhibiting the binding betw...  
WO/2017/124213A1
Provided is a joint application of a statin and a adrenocortical hormone for preparing a pharmaceutical product for treating a chronic subdural hematoma. The pharmaceutical product provided by the invention is able to accelerate hematoma...  
WO/2017/125924A1
The present invention is primarily directed to a therapeutic composition comprising caffeine, valerenic acid and 5-hydroxytryptophan (5-HTP). Additional herbal material and other natural products may also be present in the composition. T...  
WO/2017/124921A1
The present invention provides a walnut oligopeptide powder, and a preparation method and application thereof. The oligopeptide powder has a peptide content of 80 wt% or higher, wherein 95% or more of the peptides have a molecular weight...  
WO/2017/126635A1
The purpose of the present invention is to provide a heterocyclic compound having an antagonistic activity on prostaglandin E2 (PGE2) receptor subtype 2. A compound represented by formula (I) [wherein each symbol is as defined in the des...  
WO/2017/124949A1
The present invention relates to flavanone derivatives and a preparation method and use thereof, and in particular relates to the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composi...  
WO/2017/123791A1
The present invention features a neural organoid that recapitulates in vitro most characteristics of the brain (e.g., human), and methods of using this neural organoid to study disease and to identify therapeutic agents for the treatment...  
WO/2017/121646A1
The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.  
WO/2017/122722A1
The present invention provides: a compound represented by formula (1) as a pharmaceutical agent which is useful as a neuroregeneration promoting agent [in the formula, R1-L- represents R1-OC(O)-, etc., R1 represents a hydrogen atom, an o...  
WO/2017/121649A1
The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-l,3-diaza- spiro-[4.5]-decane derivatives of general formula (I), their preparation and their use in medicine, particularly in the treatment of pain.  
WO/2017/121379A1
The present application relates to a p-toluenesulfonate salt for regulating a kinase compound, and crystals thereof, and specifically, to an N-{3-[3-(9H-purine-6-group)pyridine-2-group amino]-4-chlorine-2-fluorophenyl}-3-fluoropropane-1-...  
WO/2017/124037A1
The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.  
WO/2017/123822A1
The present invention provides, in some embodiments, compounds and compositions that are SQOR substrates, and which are useful in increasing thiosulfate, decreasing hydrogen sulfide, and/or preventing an increase in hydrogen sulfide in a...  
WO/2017/121650A1
The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.  
WO/2017/121838A1
The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1 /CXCR2 receptor inhibitors, useful in the treatment and/or prevention of chemotherapy-induced neuropathy, preferably in the treatment and/or prevention of c...  
WO/2017/122789A1
Provided is a novel gene therapy means for neurological diseases including epilepsy. The present invention provides: a recombinant adeno-associated virus vector for use in the treatment of neurological diseases including epilepsy, which ...  
WO/2017/121647A1
The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.  
WO/2017/122754A1
A compound represented by general formula (I), a tautomer or stereoisomer of said compound, or a pharmaceutically acceptable salt thereof, or a solvate of these is used as a voltage-dependent T-type calcium channel inhibitor. (In the for...  
WO/2017/121648A1
The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]- decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.  
WO/2017/123820A1
The invention discloses methods of determining demand on the sulfide oxidation pathway in a human, by measuring a level of H2S, thiosulfate, and/or glutathione persulfide in a biological sample from the human. Further disclosed are metho...  
WO/2017/119455A1
Provided is a prophylactic or therapeutic agent for autism spectrum disorder, said agent comprising compound (I) that has affinity to melatonin receptors. A compound represented by formula (I) [wherein the meaning of each symbol is as de...  
WO/2017/119481A1
Provided are: a composition for preventing neurological diseases; use of a material for preventing neurological diseases; and a method for preventing neurological diseases. It has been discovered that a particular cyclic dipeptide or a s...  
WO/2017/118307A1
The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and medical uses thereof.  
WO/2017/120409A1
Described are deuterium-substituted tetrahydrocarbazole compounds of Formulae (I), (II), or (III), which are inhibitors of sirtuin 1 (SIRT1). Also described are pharmaceutical compositions comprising the deuterium-substituted tetrahydroc...  
WO/2017/118375A1
Disclosed in the present invention is a Dezocine analogue, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof.  
WO/2017/120417A1
Disclosed is a method for reducing or preventing fetal opioid dependence in a drug dependent or opioid tolerant pregnant subject. The method involves administering to the pregnant subject a composition comprising an opioid antagonist in ...  
WO/2017/119456A1
The present invention provides a prophylactic or therapeutic agent for delirium, containing a compound (I) having an affinity for a melatonin receptor. A compound represented by the formula [wherein, each symbol is as defined in the desc...  
WO/2017/119463A1
The present invention can provide a nucleic acid medicine which has a higher α-synuclein-expression-inhibiting effect and can exert this effect sustainably for a longer period. Disclosed is an oligonucleotide which contains at least one...  
WO/2017/120532A1
Provided is a phosphate salt of quinuclidin-4-ylmethyl 4-methyl-1H-indole-3- carboxylate, in particular polymorphic Form A, a process for their preparation of said salt, in particular in polymorphic Form A, and a pharmaceutical compositi...  
WO/2017/118857A1
The present invention provides tacrolimus for use in the treatment in a human subject of a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementias (FTDs), wherein the tacrolimus is for administratio...  
WO/2017/117708A1
Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing t...  
WO/2017/119198A1
It has been strongly required to develop a therapeutic drug for treating meniscus degeneration, i.e., a drug that relieves pain accompanying with meniscus degeneration, exhibits a long-lasting effect and is highly efficacious for healing...  
WO/2017/119476A1
Provided are: a composition for preventing neurological diseases; use of a material for preventing neurological diseases; and a method for preventing neurological diseases. It has been discovered that a heat-treated product of an animal/...  
WO/2017/117569A1
Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical composi...  
WO/2017/115367A1
The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject. The composition a peptid...  
WO/2017/117138A1
An apparatus for performing cerebral micro-dialysis to treat neurological disease of a patient's brain includes a catheter for implantation in or near the patient's brain, an implantable pump communicated with the catheter to transport c...  
WO/2017/117514A1
This invention relates to novel 2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1, 2,3-de]quinoxalines, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this inve...  
WO/2017/115205A1
Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.  
WO/2017/114597A1
The present invention relates to pharmaceutical dosage forms comprising the hemi-L-tartrate salt of the compound according to formula (I) in particulate form, wherein the particles have a d50 of more than 20 μm and less than 180 μm.  
WO/2017/114322A1
A traditional Chinese medicine for treating paralysis agitans is prepared from the following raw materials in parts by weight: 8 to 20 parts of herba houttuyniae, 10 to 18 parts of baked ginger, 6 to 15 parts of cymbidiumLianpan, 10 to 1...  
WO/2017/115873A1
The invention provides an agent for preventing or treating Alzheimer's disease (AD) that combines two or more compounds selected from the group consisting of compounds represented by compound numbers 1-130. These compounds are existing d...  
WO/2017/113268A1
The present invention relates to a compound for treating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and an application of the compound. The invention discloses a compound suppressing a toxicity induced by an rG...  
WO/2017/117138A8
An apparatus for performing cerebral micro-dialysis to treat neurological disease of a patient's brain includes a catheter for implantation in or near the patient's brain, an implantable pump communicated with the catheter to transport c...  
WO/2017/117121A1
Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of ...  
WO/2017/112988A1
The present invention describes molecules with a hybrid nucleus based on tetrahydroacridine and tianeptine nuclei separated by methyl spacer chains via a coupling reaction, a pharmaceutical composition comprising these molecules, a metho...  
WO/2017/117525A1
The present disclosure provides compositions, methods, systems, and apparatuses for treating disorders or illnesses. The composition may comprise at least one substance based on or derived from cocoa beans or coffee beans provided to be ...  
WO/2017/117586A1
The present invention relates to compositions that can be used, for example, in methods of treating medical conditions and symptoms associated with brain dysfunction, including but not limited to Gulf War illness (GWI), multiple chemical...  
WO/2017/114379A1
Disclosed is a nasal gel composition of glatiramer acetate, wherein same is made from glatiramer acetate, a gel matrix and other pharmaceutically acceptable excipients. The other pharmaceutically acceptable excipients comprise from 0.9%-...  
WO/2017/113775A1
The present invention provides an application of a triglyceride compound for use in preparing a medicine for treating neurodegenerative diseases.  
WO/2017/114321A1
A traditional Chinese medicine for treating viral encephalitis is prepared from the following raw materials in parts by weight: 4 to 10 parts of coastal glehnia root, 3 to 8 parts of paniculate swallowwort root, 2 to 7 parts of chastetre...  

Matches 251 - 300 out of 125,960